These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26163911)

  • 1. HDAC inhibition: A novel therapeutic target for attenuating pulmonary hypertension by regulating Tregs.
    Wang J; Saren G; Jiang H
    Int J Cardiol; 2015 Nov; 198():176-7. PubMed ID: 26163911
    [No Abstract]   [Full Text] [Related]  

  • 2. HDAC inhibition: A novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling.
    Wang J; Hu X; Jiang H
    Int J Cardiol; 2015; 190():126-7. PubMed ID: 25918063
    [No Abstract]   [Full Text] [Related]  

  • 3. HDAC inhibition: A novel therapeutic target for pulmonary hypertension by reducing right ventricular hypertrophy through diverse pathological mechanisms.
    Huang YY; Fang ZF; Hu XQ; Zhou SH
    Int J Cardiol; 2015 Oct; 196():125-6. PubMed ID: 26093160
    [No Abstract]   [Full Text] [Related]  

  • 4. HDAC inhibition: A novel therapeutic approach for attenuating heart failure by suppressing cardiac remodeling.
    Wang J; Hu X; Jiang H
    Int J Cardiol; 2016 Jul; 214():41-2. PubMed ID: 27057972
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting histone deacetylases for heart failure.
    Bush EW; McKinsey TA
    Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury.
    Zhao TC; Cheng G; Zhang LX; Tseng YT; Padbury JF
    Cardiovasc Res; 2007 Dec; 76(3):473-81. PubMed ID: 17884027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of renin-angiotensin system blockade for preventing myocardial ischemia/reperfusion injury and remodeling after myocardial infarction.
    Dai W; Kloner RA
    Postgrad Med; 2011 Mar; 123(2):49-55. PubMed ID: 21474893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats.
    Bogaard HJ; Mizuno S; Hussaini AA; Toldo S; Abbate A; Kraskauskas D; Kasper M; Natarajan R; Voelkel NF
    Am J Respir Crit Care Med; 2011 May; 183(10):1402-10. PubMed ID: 21297075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Nrf-2/ARE-HO-1 axis: An important therapeutic approach for attenuating myocardial ischemia and reperfusion injury-induced cardiac remodeling.
    Wang J; Hu X; Jiang H
    Int J Cardiol; 2015 Apr; 184():263-264. PubMed ID: 25726904
    [No Abstract]   [Full Text] [Related]  

  • 10. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
    Abend A; Kehat I
    Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme oxygenase-1: an important therapeutic target for protecting against myocardial ischemia and reperfusion injury.
    Hu X; Wang J; Jiang H
    Int J Cardiol; 2013 Jul; 167(2):587-8. PubMed ID: 23084548
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting autophagy for the therapeutic application of histone deacetylase inhibitors in ischemia/reperfusion heart injury.
    Zhang Y; Ren J
    Circulation; 2014 Mar; 129(10):1088-91. PubMed ID: 24396040
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase (HDAC) inhibition improves myocardial function and prevents cardiac remodeling in diabetic mice.
    Chen Y; Du J; Zhao YT; Zhang L; Lv G; Zhuang S; Qin G; Zhao TC
    Cardiovasc Diabetol; 2015 Aug; 14():99. PubMed ID: 26245924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
    Li G; Jiang H; Chang M; Xie H; Hu L
    J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
    Raghunathan S; Goyal RK; Patel BM
    Can J Physiol Pharmacol; 2017 Mar; 95(3):260-267. PubMed ID: 28177689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
    Chen F; Li X; Aquadro E; Haigh S; Zhou J; Stepp DW; Weintraub NL; Barman SA; Fulton DJR
    Free Radic Biol Med; 2016 Oct; 99():167-178. PubMed ID: 27498117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
    Eom GH; Kook H
    Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.